UroGen Pharma Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
URGN Nasdaq 2836 www.urogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for UroGen Pharma Ltd.

UroGen Pharma says permanent J Code for ZUSDURI now in effect - Jan 6th, 2026 6:37 am
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy - Jan 5th, 2026 6:00 am
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Dec 31st, 2025 4:58 am
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - Dec 26th, 2025 11:39 am
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 5th, 2025 6:00 am
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference - Nov 25th, 2025 6:00 am
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs - Nov 16th, 2025 8:14 pm
Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report - Nov 9th, 2025 6:25 am
Why UroGen Pharma (URGN) Is Up 15.0% After FDA Backs UGN-103 and Reports Strong Trial Results - Nov 7th, 2025 12:13 pm
UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Nov 6th, 2025 2:20 pm
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates - Nov 6th, 2025 7:15 am
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - Nov 6th, 2025 6:00 am
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial - Nov 6th, 2025 5:58 am
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference - Nov 4th, 2025 6:00 am
Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Oct 30th, 2025 8:00 am
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 - Oct 30th, 2025 6:00 am
Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates - Oct 30th, 2025 5:15 am
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? - Oct 29th, 2025 8:00 am
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026 - Oct 27th, 2025 6:00 am
MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last? - Oct 22nd, 2025 6:18 am